The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Epithelial to mesenchymal markers and clinical outcomes on erlotinib in stage IV non-small cell lung cancer patients.
Mark Pool
No relevant relationships to disclose
Mary J. Fidler
Consultant or Advisory Role - Genentech
Sanjib Basu
No relevant relationships to disclose
Brett Mahon
No relevant relationships to disclose
Lela Buckingham
No relevant relationships to disclose
Kelly Kaiser Walters
No relevant relationships to disclose
Marta Batus
No relevant relationships to disclose
Thomas A. Hensing
No relevant relationships to disclose
Jeffrey A Borgia
No relevant relationships to disclose
Philip D. Bonomi
Consultant or Advisory Role - Astellas Pharma; Genentech